For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …

Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …

Importance There are limitations in current diagnostic testing approaches for Alzheimer
disease (AD). Objective To examine plasma tau phosphorylated at threonine 217 (P-tau217) …

Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …

With the potential development of new disease-modifying Alzheimer's disease (AD)
therapies, simple, widely available screening tests are needed to identify which individuals …

Highly sensitive and specific plasma biomarkers for Alzheimer's disease (AD) have the
potential to improve diagnostic accuracy in the clinic and facilitate research studies including …

Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …

The endoplasmic reticulum (ER) is an important organelle involved in protein quality control
and cellular homeostasis. The accumulation of unfolded proteins leads to an ER stress …